ENTtoday
  • Home
  • COVID-19
  • Practice Focus
    • Allergy
    • Facial Plastic/Reconstructive
    • Head and Neck
    • Laryngology
    • Otology/Neurotology
    • Pediatric
    • Rhinology
    • Sleep Medicine
  • Departments
    • Issue Archive
    • TRIO Best Practices
      • Allergy
      • Facial Plastic/Reconstructive
      • Head and Neck
      • Laryngology
      • Otology/Neurotology
      • Pediatric
      • Rhinology
      • Sleep Medicine
    • Career Development
    • Case of the Month
    • Everyday Ethics
    • Health Policy
    • Legal Matters
    • Letter From the Editor
    • Medical Education
    • Online Exclusives
    • Practice Management
    • Resident Focus
    • Rx: Wellness
    • Special Reports
    • Tech Talk
    • Viewpoint
    • What’s Your O.R. Playlist?
  • Literature Reviews
    • Allergy
    • Facial Plastic/Reconstructive
    • Head and Neck
    • Laryngology
    • Otology/Neurotology
    • Pediatric
    • Rhinology
    • Sleep Medicine
  • Events
    • Featured Events
    • TRIO Meetings
  • Contact Us
    • About Us
    • Editorial Board
    • Triological Society
    • Advertising Staff
    • Subscribe
  • Advertise
    • Place an Ad
    • Classifieds
    • Rate Card
  • Search

How Gene Editing is Changing Otolaryngology

by Nikki Kean • December 6, 2017

  • Tweet
  • Email
Print-Friendly Version

“The CRISPR technique can now target messenger RNA [mRNA], which theoretically could solve a lot of our problems, but there are a lot of practical details that would have to be worked out, at least in the human ear,” said Lawrence R. Lustig, MD, Howard W. Smith Professor and chair of the department of otolaryngology–head and neck surgery at Columbia University College of Physicians and Surgeons in New York City. He noted, for example, that any treatment for hearing loss would have to be performed in the earliest stages of fetal development; once degenerative hearing loss begins, there is no way to reverse it.

You Might Also Like

  • Otolaryngology Research Increasingly Supports Genetic Screening to Evaluate Pediatric Hearing Loss
  • Gene Therapy: A Promising Role in Otolaryngology
  • Cochlear Implants: Changing Indications and New Technology
  • First Two Patients Respond to Gene Therapy in Melanoma Study
Explore This Issue
December 2017

To test the viability of early treatment, Dr. Lustig and his colleagues are using adeno-associate virus type 1 (AAV1) vectors very early in the mouse life cycle, day 1 after birth, “which actually translates into a human baby in utero,” he said. In one study, his team used gene replacement therapy to restore hearing in a mouse model by using the AAV1 to deliver vesicular glutamate transporter-3 (VGLUT3) cells into the cochlea of impaired mice. Within two weeks of AAV1-VGLUT3 delivery, the newborn mice had restoration of their auditory brainstem response and partial rescue of the startle response (Neuron. 2012;75:283–293).

Dr. Staecker also underscored the importance of early intervention. “CRISPR will probably have to [be applied to] dominant genes before you have complete degeneration of the hair cell in question,” he said, adding that better screening of patients also would be needed. “It is not enough just to say ,‘You have hearing loss’; we need to define what a patient has on a structural, physiologic, and molecular level,” he explained. “You want to know exactly what is wrong with the ear—whether the problem is in the stria vascularis, the hair cell, or the spiral ganglion—what are the genes involved. We will not be there tomorrow, but it will be much sooner than expected.”

Dr. Staecker was instrumental in developing the first clinical trial of human inner ear gene therapy, including evaluating the efficacy of inserting the Atoh1 gene to help regenerate vestibular hair cells (Laryngoscope. 2014;124:S1–S12). “The trial [yielded] information on how to access the ear, how to deliver treatments, what doses the human ear tolerates, and sets the stage for the more complicated therapies. If we think about gene editing or gene replacement, we may have to treat the patient for the duration of their life rather than a one-time short intervention. So we have to approach all of these things slowly.”

If we think about gene editing or gene replacement, we may have to treat the patient for the duration of their life rather than a one-time short intervention. So, we have to approach all of these things slowly. —Hinrich Staecker, MD, PhD

Downsides

The CRISPR technique holds the promise of targeting specific mutations in the DNA strand without affecting normal cells. Studies in the mouse model have run into problems, however. “There always is a risk that the technique is not selective enough to prevent the snipping of ‘normal’ portions of the strand or, potentially worse, inserting cells in the wrong place. Other concerns occur when only some of the embryo cells are repaired, called mosaicism,” Dr. Welling noted. Even in the landmark Nature study, the reported success rate was 72.4%. Most scientists agree that before this technique could be used in viable human embryos, the success rate would have to be 100% in the mouse models and larger animal studies.

Pages: 1 2 3 4 5 | Single Page

Filed Under: Departments, Home Slider, Special Reports Tagged With: clinical best practices, gene editing, gene replacement, gene replacement for hearing loss, hearing lossIssue: December 2017

You Might Also Like:

  • Otolaryngology Research Increasingly Supports Genetic Screening to Evaluate Pediatric Hearing Loss
  • Gene Therapy: A Promising Role in Otolaryngology
  • Cochlear Implants: Changing Indications and New Technology
  • First Two Patients Respond to Gene Therapy in Melanoma Study

The Triological SocietyENTtoday is a publication of The Triological Society.

The Laryngoscope
Ensure you have all the latest research at your fingertips; Subscribe to The Laryngoscope today!

Laryngoscope Investigative Otolaryngology
Open access journal in otolaryngology – head and neck surgery is currently accepting submissions.

Classifieds

View the classified ads »

TRIO Best Practices

View the TRIO Best Practices »

Top Articles for Residents

  • Do Training Programs Give Otolaryngology Residents the Necessary Tools to Do Productive Research?
  • Why More MDs, Medical Residents Are Choosing to Pursue Additional Academic Degrees
  • What Physicians Need to Know about Investing Before Hiring a Financial Advisor
  • Tips to Help You Regain Your Sense of Self
  • Should USMLE Step 1 Change from Numeric Score to Pass/Fail?
  • Popular this Week
  • Most Popular
  • Most Recent
    • The Dramatic Rise in Tongue Tie and Lip Tie Treatment
    • Vertigo in the Elderly: What Does It Mean?
    • Experts Delve into Treatment Options for Laryngopharyngeal Reflux
    • Weaning Patients Off of PPIs
    • Some Laryngopharyngeal Reflux Resists PPI Treatment
    • Vertigo in the Elderly: What Does It Mean?
    • New Developments in the Management of Eustachian Tube Dysfunction
    • Some Laryngopharyngeal Reflux Resists PPI Treatment
    • Eustachian Tuboplasty: A Potential New Option for Chronic Tube Dysfunction and Patulous Disease
    • The Dramatic Rise in Tongue Tie and Lip Tie Treatment
    • Did You Receive COVID-19 Relief? Here Are Reporting Considerations for 2021
    • Otolaryngology Experts Share Best Practices in Five Areas
    • How Climate Change May Be Affecting Sleep Patterns for Adults and Children
    • Laryngologists Discuss Tough Tracheostomy Choices During COVID-19 Era
    • Head and Neck Cancer: Experts Discuss How to Improve Surgery Quality and Value

Polls

Did you receive funding from the CARES Act or Paycheck Protection Program?

View Results

Loading ... Loading ...
  • Polls Archive
  • Home
  • Contact Us
  • Advertise
  • Privacy Policy
  • Terms of Use

Visit: The Triological Society • The Laryngoscope • Laryngoscope Investigative Otolaryngology

Wiley
© 2021 The Triological Society. All Rights Reserved.
ISSN 1559-4939

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.